* Conmed Corp CNMD.N CNMD.K is expected to show a rise
in
quarterly revenue when it reports results on October 25.
* The Largo Florida-based company is expected to report a
9.4% increase in revenue to $300.91 million from $275.09 million
a year ago, according to the mean estimate from 8 analysts,
based on Refinitiv data. The company's guidance on July 26 2023,
for the period ended September 30, was for revenue between
$295.00 million and $305.00 million.
* Refinitiv's mean analyst estimate for Conmed Corp is for
earnings of 83 cents per share. The company's EPS guidance on
July 26 2023, for the period ended September 30, was between
$0.80 and $0.85
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Conmed Corp
is
$136, above its last closing price of $94.21.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 0.79 0.79 0.83 Beat 4.5
Mar. 31 2023 0.60 0.60 0.66 Beat 10.3
Dec. 31 2022 0.89 0.90 0.42 Missed -53.5
Sep. 30 2022 0.75 0.75 0.77 Beat 2.4
Jun. 0.74 0.75 0.76 Beat 1.8
30 2022
Mar. 31 2022 0.62 0.62 0.70 Beat 13.3
Dec. 31 2021 1.03 1.03 1.07 Beat 4
Sep. 30 2021 0.75 0.75 0.80 Beat 6.7
This summary was machine generated October 23 at 22:25 GMT. All
figures in US dollars unless otherwise stated